Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)	Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cushing syndrome, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, Urogenital Abnormalities, Urogenital Diseases, adrenal gland disorder, adrenal gland hyperfunction, adrenogenital syndrome, congenital adrenal hyperplasia, disorder of sexual differentiation, ectopic ACTH secretion syndrome, endocrine system disorder, gonadal disorder, hereditary disease, inborn errors of metabolism, metabolic disease, neoplasm, paraneoplastic syndrome, steroid inherited metabolic disorder	Recruiting	Phase 2	2026-02-11		NCT07104812

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Mayo Clinic	970
RECORDATI GROUP	16

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Mayo Clinic	Rochester	United States	664